Re: Zenith Announces Annual and Special Meeting of Shareholders

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Announces Annual and Special Meeting of Shareholders

in response to

Zenith Announces Annual and Special Meeting of Shareholders

BearDownAZ

posted on Sep 16, 2019 02:01PM

Zenith AGM could be extremely interesting this year. The metastatic castrate resistant prostate cancer trial currently lists completion date of October 2019. AGM is Oct 31, 2019. This is not a blinded trial.